LYMPHOMAS

ALPHA3 highlights off-the-shelf allogeneic CAR T in community clinics, reducing leukapheresis hurdles and speeding up delivery.

Phase 2 ALPHA3 shows cema-cel in MRD-positive large B-cell lymphoma has no CRS/ICANS so far, enabling outpatient consolidation with manageable adverse effects.

Interim ALPHA3 data show cema-cel clears ctDNA MRD in high-risk DLBCL after frontline therapy, prompting continued study of consolidation CAR T.

Sonrotoclax gains FDA approval as a promising treatment for relapsed mantle cell lymphoma, showcasing strong efficacy and safety in clinical trials.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.

Discover how genomics, trial-first care, and global advocacy speed safer, targeted treatments for pediatric leukemia—beyond survival to lifelong health.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

Phase 3 FLASH2 ends early after interim analysis shows synthetic hypericin photodynamic therapy fails to improve CTCL outcomes, prompting deeper data review and regulator talks.

ZUMA-2 cohort 3 shows brexu-cel CAR T delivers 91% responses in mantle cell lymphoma, with manageable CRS/ICANS, driving full FDA approval.

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose testing and expanded eligibility, enabling full FDA approval.

Odronextamab delivers higher responses and longer control in later-line follicular lymphoma versus real-world therapies, new analysis reports.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Second-line axi-cel CAR T boosts quality of life in relapsed large B-cell lymphoma, with early dip then lasting recovery for older patients.

Venetoclax plus ibrutinib shows deep, durable responses in marginal zone lymphoma, with promising 5-year PFS and manageable safety in phase 2 AIM study.